Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens

F. Perri, V. Festa, R. Clemente, M. Quitadamo, A. Andriulli

Research output: Contribution to journalArticlepeer-review


Background: The ideal treatment for patients who have failed eradication of Helicobacter pylori infection after standard proton pump inhibitor-based triple therapies has still to be determined. Although either a second course of triple therapy or a quadruple therapy (proton pump inhibitor plus bismuth-based triple therapy) has been proposed, the efficacy of these second-line therapies is relatively unknown. Therefore, alternative strategies are needed. Aim: To assess the efficacy and tolerability of rifabutin, a derivative of rifamycin-S, in patients who were still H. pylori infected after two or more courses of 1-week triple therapies. Methods: Patients were given a 1-week: regimen of pantoprazole 40 mg b.d. + amoxycillin 1 g b.d. + rifabutin 300 mg daily. Side-effects and compliance were determined at the end of therapy. Eradication rate was assessed with a 13C-urea breath test performed at 4 and 12 weeks after treatment. Results: Forty-one patients (mean age 47 ± 15 years) were studied. All patients took medications according to the proposed schedule. Side-effects were infrequent and mild. The eradication rates were 71% (95% CI: 57-85%) on intention-to-treat analysis and 74% (95% CI: 61-88%) on per protocol analysis. Conclusions: Rifabutin, in combination with pantoprazole and amoxycillin, is an effective and well tolerated regimen in patients who failed standard eradication treatments.

Original languageEnglish
Pages (from-to)311-316
Number of pages6
JournalAlimentary Pharmacology and Therapeutics
Issue number3
Publication statusPublished - 2000

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens'. Together they form a unique fingerprint.

Cite this